Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | HTR3A | P46098 | 2/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521731 | 0.88 | HTR1A (0.35) | HTR1AHTR3AATMALDH1A1 | |
| SCHEMBL20662478 | 0.85 | CD274 (0.33) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL4507192 | 0.76 | HTR1A (0.37) | CYP1A2CYP3A4HTR1ACYP2D6CYP2C9 | |
| SCHEMBL20627170 | 0.75 | LDHA (0.33) | ALDH1A1KDM4E | |
| SCHEMBL4521726 | 0.71 | SMN1; SMN2 (0.39) | ALDH1A1SMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL8194084 | 0.70 | ALDH1A1 (0.40) | CYP1A2CYP2D6CYP2C9ALDH1A1KDM4E | |
| SCHEMBL4531563 | 0.70 | ALDH1A1 (0.40) | CYP1A2CYP2D6CYP2C9ALDH1A1KDM4E | |
| SCHEMBL24512337 | 0.67 | NPY5R (0.35) | CD274PDCD1 | |
| SCHEMBL20662465 | 0.67 | DDB1 (0.39) | ALDH1A1HPGD | |
| SCHEMBL20662496 | 0.65 | CCR5 (0.38) | ALDH1A1KDM4EMEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156831-A1 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | MERLI VALERIANO | 2009-06-18 | — | — | US | disclosed |
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-10-30 | — | — | US | disclosed |
| US-20080214835-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-09-04 | — | — | US | disclosed |
| EP-1877393-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-01-16 | — | — | EP | disclosed |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-30 | — | — | US | disclosed |
| WO-2007076158-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214835-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | CYP1A2 2087/4885CYP3A4 1593/4885HTR1A 1244/4885 |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | CHRNE, CHRM3, CHRM2 | CYP1A2 1365/4885CYP3A4 3608/4885HTR1A 220/4885 |
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | CYP1A2 2087/4885CYP3A4 1593/4885HTR1A 1244/4885 |
| US-20090156831-A1 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | OPRL1, AVPR2, AVPR1B | CYP1A2 2087/4885CYP3A4 1593/4885HTR1A 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.